Investments in progress
We are currently investing in one or more companies that passed our rigorous selection process. Please login or create an account to learn more and co-invest with us.
Our portfolio companies
Our portfolio companies are currently developing diagnostics for early detection of cancer via blood sample, saving lives in emergency care and surgery through software innovations, developing personalised treatments of severe diseases, and much more.
NEOGAP Therapeutics AB
NEOGAP has a unique approach to train the patient’s immune system to target tumour-specific mutations, so called neoantigens to eradicate the cancer. The treatment has the potential to kill the cancer cells while leaving healthy cells untouched, which significantly reduces the risk of side effects.
Synartro
Synartro is developing a unique treatment for knee osteoarthritis by combining two well-tried drugs, which will offer an effective and safe alternative to today’s treatments.
SAGA Diagnostics
SAGA Diagnostics develops ultrasensitive liquid biopsy tests for early detection of cancer relapse and personalized cancer treatment. The tests are based on the company’s proprietary technologies for analyzing circulating tumor DNA (ctDNA).
Cavis Technologies
Cavis Technologies has developed a combined guidewire/catheter, Wirecath®, for diagnosis of people with coronary heart disease. Wirecath® is expected to provide important clinical benefits.
Exits
Former portfolio companies that have reached new heights through acquisition or listing, and continue to thrive under new ownership. These companies continue to make a lasting impact in their respective industries.
Inhalation Sciences
Inhalation Science’s technology is used by leading players in the chemical and pharmaceutical sectors to study how airborne particles affect the human body.
Read more
Lipigon Pharmaceuticals
Lipigon develops orphan drugs for illnesses due to disorders in how the body handles fat. The company’s major program, Lipsense, focuses on the illness, HoFH, where there is, today, no sufficient treatment.
Read more